Northern Trust Corp Purchases 634,045 Shares of InflaRx (NASDAQ:IFRX)

Northern Trust Corp raised its stake in shares of InflaRx (NASDAQ:IFRX - Free Report) by 1,933.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 666,845 shares of the company's stock after purchasing an additional 634,045 shares during the period. Northern Trust Corp owned 1.13% of InflaRx worth $1,647,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of IFRX. Raymond James Financial Inc. bought a new stake in InflaRx in the 4th quarter valued at about $1,576,000. Commonwealth Equity Services LLC increased its position in InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after buying an additional 19,000 shares in the last quarter. Geode Capital Management LLC increased its position in InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after buying an additional 11,900 shares in the last quarter. Walleye Capital LLC bought a new stake in InflaRx in the 4th quarter valued at about $51,000. Finally, Two Sigma Securities LLC bought a new stake in InflaRx in the 4th quarter valued at about $28,000. 42.39% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on IFRX shares. Oppenheimer decreased their target price on InflaRx from $6.00 to $3.00 and set an "outperform" rating for the company in a research report on Thursday. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of InflaRx in a research report on Friday, March 21st. Cantor Fitzgerald began coverage on InflaRx in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 target price for the company. Raymond James downgraded InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target for the company. in a research note on Thursday. Finally, Guggenheim boosted their price objective on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, March 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat, InflaRx currently has a consensus rating of "Buy" and an average target price of $6.60.

InflaRx Price Performance

Shares of NASDAQ:IFRX traded down $0.05 during trading on Friday, hitting $0.81. 508,905 shares of the company were exchanged, compared to its average volume of 270,964. The company has a market cap of $54.04 million, a PE ratio of -0.75 and a beta of 1.57. The stock has a 50 day moving average of $1.33 and a 200 day moving average of $1.83. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.03 million. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. Sell-side analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.